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Abstract 20 
The use of agrochemicals for crop protection may result in the presence of toxic residues in soils and 21 
aquatic environments, besides in foodstuffs. Most often just the parent compound is included in the 22 
definition of pesticide residue, even though chemicals resulting from biotransformation and degradation 23 
routes might also be of toxicological relevance. Azoxystrobin is a broad-spectrum systemic fungicide widely 24 
used worldwide to combat pathogenic fungi affecting plants. We herein report the synthesis and detailed 25 
chemical characterization of several of the most relevant metabolites and degradates of azoxystrobin. 26 
These compounds were further employed as ligands for screening a collection of monoclonal antibodies to 27 
azoxystrobin, which had been previously generated from haptens functionalized at different positions of 28 
the target chemical. As a result, an antibody was identified capable of binding, with subnanomolar affinity, 29 
not only azoxystrobin but also its main transformation products, such as the so-called acid and enol 30 
derivatives, as well as the azoxystrobin (Z)-isomer. The selected binder was demonstrated as a useful 31 
immunoreagent for the development of immunochemical assays as novel analytical tools for the qualitative 32 
determination of azoxystrobin and its metabolites and degradates. 33 
 34 
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1. Introduction 40 
Modern agricultural practices strongly rely on the use of plant protection chemicals that can provide the 41 
required crop yields in order to feed an ever-growing human population with high quality and inexpensive 42 
foods. Even though pesticides are usually applied according to the rules of Good Agricultural Practices, 43 
residues are regularly detected in agricultural commodities and in aquatic environments. The presence of 44 
trace amounts of this sort of xenobiotics might result in adverse consequences to humans and to non-45 
target organisms. Hence, these substances need to be strictly controlled to safeguard human health and to 46 
protect the environment. In addition, the presence of multiple pesticide residues, even at low 47 
concentrations, may induce higher toxicological and carcinogenic effects. Pesticide transformation 48 
products, both metabolites and degradates, are also an issue of concern because they may feature harmful 49 
properties comparable to or higher than those of the active parent substance, and they may cause synergic 50 
noxious effects. Nevertheless, breakdown compounds are only occasionally included in the definition of 51 
pesticide residue, either because they are of lower toxicity or they are not present in significant amounts, 52 
or just because reference standards are not easily available.  53 
Among pesticides, the presence of fungicide residues in foodstuffs is increasingly becoming of greater 54 
relevance since a better protection of fruits and vegetables after harvesting must be ensured. The 55 
agrochemical industry is continuously pursuing the discovery of new biocides acting at novel molecular 56 
targets and simultaneously being less toxic to humans and the environment. One such novel group of 57 
synthetic chemicals is the strobilurin family of fungicides. Their discovery was inspired by the identification, 58 
in the mushrooms Strobilurus tenacellus and Oudemansiella mucida, of a group of active natural products 59 
displaying a potent antifungal activity (Anke et al., 1977; Sauter et al., 1999). Strobilurins exert their 60 
biological action by binding to the Qo site of the cytochrome b in the mitochondrial electron transport 61 
chain (Balba, 2007). The first patented strobilurin was azoxystrobin (1, Fig. 1), which is currently approved 62 
worldwide for disease control in most cereal, fruit, and vegetable crops. Over 4000 tones of this fungicide 63 
were used worldwide in 2009, with global annual sales above $1 billion, which makes this substance the 64 
world’s leading proprietary fungicide (Atkin, 2010). According to the European Pesticide Monitoring 65 
Programs (EFSA, 2009), azoxystrobin was among the most frequently found pesticides in foodstuffs; around 66 
5% of the analyzed fruit and vegetable samples contained residues at or below the tolerance levels. 67 
Azoxystrobin has low acute and chronic toxicity to humans, birds, mammals, and bees (US EPA, 1997; 68 
Bartlett et al., 2002). However, it is considered toxic to freshwater fish, freshwater invertebrates, and 69 
estuarine/marine fish, and highly toxic to estuarine/marine invertebrates (PMRA, 2000; Gustafsson et al., 70 
2010). Recently, some limited adverse effects have been observed on Atlantic salmon smolts (Olsvik et al, 71 
2010), on Daphnia magna (Warming et al., 2009; Friber-Jensen et al, 2010), and on Rana temporaria spawn 72 
and tadpoles (Johansson et al, 2006). 73 
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Surprisingly, very few independent data exist, in the regular scientific literature, about azoxystrobin 74 
transformation products and their toxicity to different organisms. As a matter of fact, most of the available 75 
information comes from registration documents provided by the manufacturer (Adetutu et al., 2008). 76 
Likewise, novel analytical methods for azoxystrobin and its major metabolites and degradation products 77 
have hardly ever been reported (Kern et al., 2009). In order to unequivocally identify unknown compounds, 78 
combined MS and NMR data of the purified substances are required. Besides, analytical reference 79 
standards for the most relevant derivatives are needed so as to improve our understanding of the overall 80 
presence of those chemicals in the environment and their toxicological relevance. In this work, we describe 81 
the synthesis and the complete spectroscopic characterization of five compounds widely recognized as 82 
major degradates of azoxystrobin. Additionally, this group of chemicals was used to screen a collection of 83 
in-house developed monoclonal antibodies (mAbs) with the aim of finding biomolecules that could 84 
recognize with high affinity not only azoxystrobin but also its main transformation products. Antibodies 85 
with such features may be greatly valuable for the development of rapid screening methods, such as the 86 
competitive enzyme-linked immunosorbent assays (cELISA), which can provide high-throughput capacity 87 
and reliable results on the occurrence of this relevant biocide and its breakdown compounds in food, 88 
biological, and environmental samples. 89 
 90 
2. Materials and methods 91 
2.1. Reagents and instrumentation 92 
Analytical-grade azoxystrobin (methyl (E)-2-{2-[6-(2-cyanophenoxy)pyrimidin-4-yloxy]phenyl}-3-93 
methoxyacrylate) (CAS number 131860-33-8, MW 403.4 g/mol) was kindly provided by Syngenta (Basel, 94 
Switzerland). Other reagents and solvents were acquired from commercial sources and were used without 95 
purification. The reactions were monitored with the aid of thin-layer chromatography (TLC) using 0.25 mm 96 
pre-coated silica gel plates. Visualization was carried out with UV light and aqueous ceric or ammonium 97 
molybdate solution at 50% (v/v). Chromatography refers to flash column chromatography and it was 98 
carried out with the indicated solvents on silica gel 60 (particle size 0.040−0.063 mm). All operations 99 
involving air-sensitive reagents were performed under an inert atmosphere of dry nitrogen using syringe 100 
and cannula techniques, oven-dried glassware, and freshly distilled and dried solvents. Melting points (Mp) 101 
were determined using a Kofler hot-stage apparatus or a Büchi melting point apparatus, and they are 102 
uncorrected. NMR spectra were recorded in CDCl3 or CD3OD at room temperature on a Bruker AC-300 103 
spectrometer (300.13 MHz for 1H and 75.47 MHz for 13C). The spectra were referenced to residual solvent 104 
protons in the 1H NMR spectra (7.26 ppm for CDCl3 and 4.84 and 3.31 ppm for CD3OD) and to solvent 105 
carbons in the 13C NMR spectra (77.0 ppm for CDCl3 and 49.05 ppm for CD3OD). Carbon substitution 106 
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degrees were established by distortionless enhancement by polarization transfer (DEPT) pulse sequences. 107 
Complete assignment of 1H and 13C chemical shifts of all compounds was made on the basis of a 108 
combination of correlation spectroscopy (COSY) and heteronuclear single quantum coherence (HSQC) 109 
experiments. Infrared (IR) spectra were measured as thin films between NaCl plates for liquid compounds 110 
and as KBr pellets for solids using a Nicolet Avatar 320 spectrometer. The peak intensity is given as strong 111 
(s), medium (m) or weak (w). MS and high-resolution MS (HRMS) were run either by the electron impact 112 
(EI, 70 eV) or fast atom bombardment (FAB) mode, obtained with a Micromass VG Autospec spectrometer, 113 
or the electrospray (ES) mode, which was acquired with a Q-TOF premier mass spectrometer with an 114 
electrospray source (Waters, Manchester, UK). 115 
The production of the mAbs that were used in this work was carried out in our laboratory following 116 
standard procedures for the generation of hybridoma cell lines (unpublished results), whereas the synthesis 117 
of the haptens that were employed for immunization (Fig. S1 in the Supplementary Data File) and their 118 
conjugation to carrier proteins have been previously reported (Parra et al., 2011a). o-Phenylenediamine 119 
was purchased from Sigma-Aldrich (Madrid, Spain) and polyclonal rabbit anti-mouse immunoglobulin 120 
peroxidase conjugate (RAM–HRP) was from Dako (Glostrup, Denmark). Costar flat-bottom high-binding 121 
polystyrene ELISA plates were from Corning (Corning, NY, USA). Microplates were washed with an ELx405 122 
washer from BioTek Instruments (Winooski, VT, USA) and the ELISA absorbances were read in dual 123 
wavelength mode with a PowerWave HT also from BioTek Instruments. 124 
The composition, concentration, and pH of the buffers employed in this study were as follows: i) CB, 125 
50 mM carbonate–bicarbonate buffer, pH 9.6; ii) PBS, 10 mM sodium phosphate buffer, pH 7.4 with 140 126 
mM NaCl; iii) PBST, PBS containing 0.05% (v/v) Tween 20; iv) Washing solution, 150 mM NaCl and 0.05% 127 
(v/v) Tween 20; and v) Enzyme substrate buffer, 25 mM sodium citrate and 62 mM sodium phosphate 128 
buffer, pH 5.4. 129 
2.2. Synthesis of azoxystrobin transformation products 130 
Spectroscopic characterization data of the synthesized compounds described below can be found in the 131 
Supplementary Data File. 132 
2.2.1. Preparation of (E)-2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl)-3-methoxyacrylic acid (AZ-acid, 133 
2) and (Z)-methyl 2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl)-3-hydroxyacrylate (AZ-enol, 3) 134 
Isopropanol (12.7 mL) and H2O (6.1 mL) were successively added to a mixture of azoxystrobin (1, 513.8 135 
mg, 1.27 mmol) and LiOH∙H2O (532 mg, 12.7 mmol); see Fig. 1A. The resulting yellowish suspension was 136 
stirred at room temperature (rt) for 3 h, then poured into water and extracted three times with ethyl ether. 137 
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The aqueous layer was reserved and the combined organic layers were washed with brine and dried over 138 
anhydrous Na2SO4. Filtration and evaporation of the solvent under reduced pressure afforded a solid 139 
corresponding to unreacted azoxystrobin (210 mg, 41%). The aqueous phase was cooled in an ice bath and 140 
acidified with stirring to pH 3 by the addition of solid KHSO4. The resulting yellow suspension was extracted 141 
with ethyl ether and the combined organic layers were washed with brine and dried over anhydrous 142 
Na2SO4. The residue remaining after evaporation of the solvent was purified by chromatography, using 143 
mixtures of increasing polarity of CHCl3–MeOH (from 99:1 to 90:10) as eluent, to give, in order of elution, 144 
AZ-enol (3, 198 mg) as a yellowish oil and AZ-acid (2, 43 mg) as a white solid (mp 85–87 °C crystallized from 145 
CH2Cl2–hexane). These amounts correspond to yields of 68% and 15%, respectively, based on recovered 146 
starting material. 147 
 148 
2.2.2. Preparation of (Z)-Methyl 2-(2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)phenyl)-3-methoxyacrylate 149 
(AZ-Z, 5) 150 
The photoisomerization product of azoxystrobin, Z-stereoisomer 5, was prepared from azoxystrobin (1) 151 
as shown in Fig. 1A following a reported procedure (Clough et al., 1992). Spectroscopic data, not previously 152 
described in the literature, allowing a complete and unequivocal structural characterization of this 153 
compound are given in the Supplementary Data File. 154 
 155 
2.2.3. Preparation of 2-(6-hydroxypyrimidin-4-yloxy)benzonitrile (AZ-pyOH, 8) 156 
2.2.3.1. Synthesis of 4-tert-butoxy-6-chloropyrimidine (6)  157 
A 1 M solution of potassium tert-butoxide in tetrahidrofuran (THF) was dropwise added (2.18 mL, 2.18 158 
mmol) under nitrogen into a solution of 4,6-dichloropyrimidine (325.7 mg, 2.18 mmol) in anhydrous THF 159 
cooled to 0 °C (Fig. 1B). The resulting orange mixture was stirred at 0 °C for 90 min, then poured into water 160 
and extracted with EtOAc. The combined organic layers were washed with brine and dried over anhydrous 161 
Na2SO4. The solvent was carefully eliminated in the rotavapor (the compound formed is relatively volatile), 162 
and the residue left was purified by chromatography, using hexane–EtOAc 9:1 as eluent, to give the tert-163 
butoxypyrimidine 6 (315 mg, 75%) as a colorless oil. 164 
  165 
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2.2.3.2. Synthesis of 2-(6-tert-butoxypyrimidin-4-yloxy)benzonitrile (7) 166 
Anhydrous N,N-dimethylformamide (DMF, 2.5 mL) was added to a mixture of tert-butoxypyrimidine 6 167 
(123.5 mg, 0.662 mmol), 2-cyanophenol (94.63 mg, 0.794 mmol), and Cs2CO3 (323.53 mg, 0.993 mmol) 168 
under nitrogen. The mixture was stirred at 110 °C for 18 h, then cooled to rt, poured into water, and 169 
extracted with EtOAc. The organic layer was washed consecutively with 10% aqueous NaOH, water, and 170 
brine and dried over anhydrous Na2SO4. Evaporation of the solvent afforded compound 7 (166 mg, 99%) as 171 
a white solid (mp 88–90 °C crystallized from CH2Cl2–hexane) that was pure enough, as judged by 
1H NMR, 172 
to be used in the next step without further purification.  173 
 174 
2.2.3.3. Synthesis of 2-(6-hydroxypyrimidin-4-yloxy)benzonitrile (8) 175 
Trifluoroacetic acid (1 mL) was dropwise added under nitrogen to a stirred solution of tert-176 
butoxypyrimidine 7 (57.3 mg, 0.212 mmol) in anhydrous CH2Cl2 (1 mL) cooled at 0 °C (Fig. 1B). The mixture 177 
was stirred at rt for 20 min, then diluted with benzene and concentrated to dryness under reduced 178 
pressure to give a nearly quantitative yield of AZ-pyOH (8, 45 mg) as a pure yellowish solid. Mp 200–202 °C 179 
(crystallized from CH2Cl2–MeOH). 180 
 181 
2.2.4. Preparation of 2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)benzoic acid (AZ-benzoic, 11)  182 
2.2.4.1. Synthesis of 2-(6-chloropyrimidin-4-yloxy)benzonitrile (9) 183 
A mixture of 2-cyanophenol (262 mg, 2.19 mmol), 4,6-dichloropyrimidine (326 mg, 2.19 mmol), and 184 
Cs2CO3 (1.07 g, 3.29 mmol) in anhydrous DMF (7.5 mL) was stirred at rt under nitrogen for 3 h. The mixture 185 
was poured into water, extracted with EtOAc, and the combined extracts washed with brine, dried over 186 
anhydrous Na2SO4, and concentrated under vacuum to leave a yellowish oil of nearly pure compound 9 187 
(505 mg, 99%), which was used in the next step without further purification.  188 
2.2.4.2. Synthesis of methyl 2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)benzoate (10) 189 
A solution of the chloropyrimidine 9 (91.2 mg, 0.393 mmol), methyl salicilate (92.7 mg, 0.609 mmol), 190 
and Cs2CO3 (256 mg, 0.786 mmol) in anhydrous DMF (2 mL) was stirred at 100 °C for 90 min under nitrogen. 191 
The mixture was cooled to rt, poured into water and extracted with EtOAc. The acetate extracts were 192 
washed with a cooled 10% aqueous solution of NaOH to remove the excess of phenol, washed with brine, 193 
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dried over anhydrous Na2SO4, and concentrated under vacuum to yield the methyl benzoate 10 (136 mg, 194 
99%) as a colourless oil.  195 
 196 
2.2.4.3. Synthesis of 2-(6-(2-cyanophenoxy)pyrimidin-4-yloxy)benzoic acid (11) 197 
A suspension of 10 (49.6 mg, 0.142 mmol) and LiOH∙H2O (59.58 mg, 1.42 mmol) in a mixture of 198 
isopropanol (0.75 mL) and water (0.68 mL) was stirred at rt for 45 min (Fig. 1B). The resulting clear solution 199 
was poured into water and extracted with EtOAc to recover unreacted starting material. The aqueous 200 
phase was acidified with KHSO4 to pH 2–3 and the precipitated acid was extracted with EtOAc. The organic 201 
layer was washed with brine, dried over anhydrous Na2SO4, and evaporated to dryness to obtain AZ-202 
benzoic (11, 41 mg, 87%) as a white solid. Mp 128–130 oC (crystallized from CH2Cl2–MeOH). 203 
 204 
2.3. ELISA procedure 205 
Conjugate-coated indirect cELISAs were employed for metabolite recognition experiments by mAbs. 206 
Ninety-six-well polystyrene ELISA plates were coated by overnight incubation at rt with 100 µL solutions of 207 
OVA–hapten conjugates. Coated plates were washed four times with washing solution and received, 208 
afterwards, 50 µL per well of analyte standard (or metabolite) in PBS plus 50 µL per well of mAb solution in 209 
PBST. After 1 h at rt of immunological reaction, plates were washed as described before. Next, 100 µL per 210 
well of a 1/2000 dilution of RAM–HRP conjugate in PBST was added and incubated again 1 h at rt. After 211 
washing, the signal was obtained by addition of 100 µL per well of freshly prepared 2 mg/mL 212 
o-phenylenediamine solution containing 0.012% (v/v) H2O2 in enzyme substrate buffer. The enzymatic 213 
reaction was stopped after 10 min at rt with 100 µL per well of 2.5 M sulfuric acid. The absorbance was 214 
immediately read at 492 nm with a reference wavelength at 650 nm. 215 
2.4. Standards and data treatment 216 
Eight-point standard curves of azoxystrobin and transformation products were prepared from 217 
concentrated stock solutions in anhydrous DMF by serial dilution in PBS, including a blank point. 218 
Experimental values were fitted to a four-parameter logistic equation using the SigmaPlot software package 219 
from SPSS Inc. (Chicago, IL, USA). Assay sensitivity was defined as the concentration of analyte at the 220 
inflection point of the fitted curve, typically corresponding to a 50% inhibition (IC50) of the maximum 221 
absorbance (Amax) if the background signal approaches to zero. Cross-reactivity was calculated as the 222 
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percentage of the ratio between the IC50 value for azoxystrobin and the IC50 value for the corresponding 223 
transformation product. 224 
2.5. Buffer studies 225 
The influence of ionic strength, pH, and Tween 20 concentration over the antibody–antigen interaction 226 
was evaluated following a multiparametric approach. The selected model was based on a central composite 227 
design. Briefly, a full factorial design was performed with 3 factors that included 8 cube, 6 axial, and 6 228 
central points, with 3 replicates each located at random positions, involving a total of 15 buffers. Ionic 229 
strength values ranging from 50 to 300 mM, pH values from 5.5 to 9.5, and Tween 20 concentrations from 230 
0.00 to 0.05% (v/v) were used as axial points. Buffer characteristics used in this study are shown in Table S1 231 
of the Supplementary Data File and they were prepared as follows. First, a 40 mM trisodium citrate, 40 mM 232 
disodium hydrogen phosphate, and 40 mM Tris solution (pH 9.9) was prepared, and known volumes of 5 M 233 
HCl were added in order to achieve the desired pH in each case. Then, the ionic strength of each solution 234 
was calculated, considering the initial solution and the employed volume of HCl, and the appropriate 235 
volume of a 2 M NaCl solution was added to every buffer aliquot in order to achieve the required ionic 236 
strength. Finally, Tween 20 was included at the corresponding concentration before the final volume was 237 
achieved by addition of deionized water. The concentration of Tween 20 and the ionic strength of the 238 
buffers were twice the final values in the assays. For the evaluated antibody (mAb AZa6#210), OVA–hapten 239 
coated microplates were prepared (OVA–AZa6 at 0.1 µg/mL) and cELISAs were carried out using 240 
azoxystrobin standard curves in water, whereas mAb solutions (80 ng/mL) were prepared in every 241 
evaluated buffer. Changes in the inhibition curve parameters were fitted by a multiple regression equation, 242 
including curvature and interaction terms, using Minitab 14.1 software (Minitab Inc., State College, PA, 243 
USA). 244 
3. Results and discussion 245 
3.1. Preparation of azoxystrobin transformation products 246 
The major metabolite and degradation compound of azoxystrobin in aerobic soils, anaerobic soils, and 247 
water-sediment systems was reported to result from hydrolysis of the methyl ester moiety to form the 248 
β-methoxyacrylic acid (AZ-acid, 2) (Ghosh and Singh, 2009; Singh et al., 2010). Because AZ-acid (2) is known 249 
to be very soluble in water (860 mg/L), this compound will likely leach to groundwater. Other minor 250 
degradation products identified under environmental conditions include AZ-pyOH (8) and AZ-benzoic (11) 251 
(Joseph, 1999; Boudina et al., 2007). Likewise, although azoxystrobin is a relatively stable pesticide with 252 
regard to photodegradation under natural sunlight conditions, the (Z)-isomer of azoxystrobin (AZ-Z, 5) was 253 
identified as the main product of photochemical transformation under UV irradiation (Boudina et al., 2007). 254 
10 
 
Other breakdown products tentatively identified by HPLC–MS in the same study included, but were not 255 
restricted to, AZ-enol (3) and compounds 8 and 11. The presence of trace levels of the biocide, and even 256 
AZ-acid (2), in natural aquatic environments has also been reported (Kern et al., 2009; Warming et al., 257 
2009). 258 
Azoxystrobin is extensively metabolized in animals and plants. The major metabolite in mammals is 259 
AZ-acid (2), which subsequently undergoes conjugation to form the corresponding glucuronide. Other 260 
identified metabolic pathways include hydroxylation on the cyanophenyl ring followed by conjugation, and 261 
the cleavage of the ether linkage between aromatic rings to give AZ-pyOH (8) (Joseph, 1999; Laird et al., 262 
2003; JMPR, 2008). Most animal metabolites have been also found in plants, with the remarkable exception 263 
of AZ-Z (5), which was identified in plants but not in animals (Joseph, 1999), besides arising from 264 
photochemical transformation, as described above. 265 
Based on those precedents, relevant azoxystrobin transformation products intended for antibody 266 
recognition studies were prepared from readily available starting materials. Compounds 2, 3, and 5, which 267 
preserve most of the molecular framework, were obtained from technical-grade fungicide (Fig. 1A). The 268 
preparation of AZ-acid (2), the major metabolite of azoxystrobin, was more difficult than initially expected. 269 
Under smooth acidic conditions, the original molecule was recovered practically unchanged, but under 270 
more severe settings (HCl in isopropanol–water, 100 °C) the major observed reactions involved hydrolytic 271 
ether cleavage between the aromatic rings and hydrolysis of the nitrile group. On the other hand, complex 272 
reaction mixtures were obtained under most of the basic tested conditions. From a synthetic point of view, 273 
the best results were obtained by treatment of azoxystrobin with LiOH in a mixture of isopropanol–water at 274 
rt for a short period of time. Unlike previous results reported by Kern et al. (2009), who under similar 275 
hydrolytic conditions observed a single peak by HPLC that they ascribed to AZ-acid (2), we detected by TLC 276 
the formation of two major compounds. Both products, which could be readily separated by flash column 277 
chromatography on silica gel, were analyzed by MS and HRMS, showing the same molecular mass (389.1 278 
g/mol) but clearly different fragmentation patterns (Fig. 2). In order to definitely identify each 279 
transformation product, a detailed 1H and 13C NMR spectroscopy study was carried out (see the 280 
Supplementary Data File). As a result, the most abundant hydrolytic compound was unambiguously 281 
identified as the AZ-enol 3 (68% yield based on recovered unreacted starting material) while the other 282 
substance could be identified as the acid metabolite 2 (15% yield). The preference for the formation of the 283 
enol derivative under basic hydrolysis conditions was also confirmed with picoxystrobin, a strobiluring 284 
fungicide bearing in its structure the same methyl β-methoxyacrylate moiety than azoxystrobin (Parra et 285 
al., 2011b). Finally, it is worthy to note that enol 3 exists, at least in CDCl3 solution, with the (Z)-geometry of 286 
the double bond, which seems to be stabilized by formation of an intramolecular hydrogen bond between 287 
the hydroxyl proton and the carbonyl oxygen.  288 
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The synthesis of the azoxystrobin photoproduct, the (Z)-isomer 5, was also accomplished from 289 
azoxystrobin (Fig. 1A) following a literature procedure (Clough et al., 1992). This strategy involved the 290 
oxidative cleavage of the acrylate double bond to give keto-ester 4, from which the methoxymethylene 291 
moiety was regenerated by means of a Wittig reaction. The last reaction is not stereoselective, leading to a 292 
nearly equimolecular mixture of (E)- and (Z)-isomers, from which compound 5 could be separated, in about 293 
22% yield based on recovered starting material, and spectroscopically characterized. 294 
The synthesis of the two other intended transformation products of azoxystrobin (compounds 8 and 11) 295 
was undertaken starting from 4,6-dichloropyrimidine (Fig. 1B) via nucleophilic aromatic substitution of the 296 
chlorine atoms by the required oxygenated moieties (Parra et al., 2011a). For the synthesis of 8, all 297 
attempts to directly introduce the hydroxyl group failed, so it was incorporated in the form of a tert-298 
butoxide group and ultimately released in due course by acid hydrolysis. Thus, treatment of 299 
4,6-dichloropyrimidine with an equivalent of potassium tert-butoxide in THF at rt (Kofink and Knochel, 300 
2006) afforded the tert-butoxide derivative 6, which was subjected to another nucleophilic substitution 301 
reaction of the chlorine atom with 2-cyanophenol, using in this case more vigorous conditions, to give 7. 302 
The final step that led to pyrimidinol 8 involved acid-promoted cleavage of the tert-butyl ether moiety, 303 
which took place very efficiently by treatment of intermediate 7 with trifluoracetic acid at rt. The synthesis 304 
of the benzoic acid derivative 11 was achieved, as before, through two consecutive nucleophilic aromatic 305 
substitution reactions. First, 4,6-dichloropyrimidine was reacted under very smooth basic conditions with 306 
2-cyanophenol to afford pyrimidinyl-aryl ether 9, which then reacted with methyl 2-hydroxybenzoate to 307 
give compound 10 under conditions similar to those previously used for the transformation of 6 into 7. 308 
Finally, base-catalyzed hydrolysis of the methyl ester moiety of 10 provided AZ-benzoic (11) in very high 309 
overall yield from 4,6-dichloropyrimidine. 310 
All the synthesized products were characterized using widely available instrumentation instead of 311 
sophisticated equipment in order to facilitate the identification of azoxystrobin transformation products 312 
under less demanding situations. To this purpose, degradates were analyzed by HPLC-DAD employing two 313 
different gradient systems, i.e., mixtures of MeOH–H2O and MeCN–H2O (Table 1). Under both conditions, 314 
the two azoxystrobin stereoisomers eluted with clearly different retention times. However, none of the 315 
assayed eluents was able to properly resolve the structural isomers AZ-acid and AZ-enol; indeed, with 316 
mixtures of MeCN–H2O also AZ-benzoic coeluted with AZ-acid and AZ-enol. On the other hand, with the 317 
MeOH–H2O gradient, AZ-benzoic separated from these two isomers but coeluted with AZ-pyOH. These 318 
results emphasize the actual complexity of distinguishing between AZ-acid and AZ-enol, given their similar 319 
chromatographic behaviour and identical mass. Fortunately, all five transformation products migrated 320 
separately by TLC using a CHCl3–MeOH mixture (98:2, v/v). As a matter of fact, AZ-acid and AZ-enol clearly 321 
separated from each other by TLC (Rf values of 0.21 and 0.68, respectively), which makes this analytical 322 
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procedure a simple method to differentiate between these two azoxystrobin degradates (Table 1). The 323 
product with the lowest Rf value (0.10) was AZ-benzoic. This result contrasts with that obtained by Singh et 324 
al. (2010), who reported an Rf value for AZ-benzoic of 0.62, higher than the value they gave for AZ-acid 325 
(0.175) and very similar to that of azoxystrobin itself (0.71). 326 
3.2. Recognition of azoxystrobin transformation products by a collection of mAbs 327 
Antibodies are binding biomolecules most often exhibiting outstanding specificity to their target 328 
antigen. In the case of mAbs against low molecular mass analytes, the recognition profile to structurally 329 
related compounds is however greatly influenced by the structure of the immunizing hapten (Suárez-330 
Pantaleón et al., 2011). With this idea in mind, we decided to test a collection of anti-azoxystrobin mAbs for 331 
their ability to also recognize, with high affinity, the transformation products described above. The assayed 332 
panel of mAbs was produced in our laboratory following standard cell culture techniques from mice 333 
immunized with haptens bearing, as reactive chemical group for protein coupling, a carboxylic linker 334 
tethered at different positions of the azoxystrobin molecular framework (Fig. S1). 335 
The binding properties of our antibody library were examined by performing inhibition experiments in 336 
the homologous indirect cELISA format with standard solutions of the azoxystrobin transformation 337 
products (from 105 to 10−2 nM, plus a blank). First, competitive checkerboard experiments were run in 338 
order to determine the adequate concentration of each immunoreagent combination for an optimal 339 
competition. Our aim was to identify an antibody capable of equally recognizing azoxystrobin and most of 340 
its breakdown compounds. To this purpose, IC50 values for each mAb/degradate pair were obtained and 341 
used to calculate cross-reactivities as described in the Materials and Methods section (Table 2). Not 342 
surprisingly, no mAb was able to noticeably recognize AZ-pyOH, most likely because this compound lacks 343 
one of the three aromatic rings that constitute the whole azoxystrobin molecule. Similarly, most mAbs did 344 
not bind AZ-benzoic, thus emphasizing the importance of the acrylate moiety in the antibody interaction 345 
with the fungicide. Only two mAbs, AZa6#26 and AZa6#210, bound this degradate to a slight degree (4.69% 346 
and 6.19%, respectively). Concerning recognition of compounds AZ-Z, AZ-acid, and AZ-enol, several mAbs 347 
could clearly accommodate them at their binding sites. These antibodies were mainly found among those 348 
sets deriving from immunizing haptens AZa6 and AZc6 (Fig. S1). In particular, five out of eight mAbs from 349 
these two groups bound AZ-Z with sound affinity. This result is particularly relevant because both 350 
azoxystrobin stereoisomers are included in the residue definition of the regulations laid down by countries 351 
such as Canada (PMRA, 2000), United States (US EPA, 2008), and New Zealand (NZFSA, 2011), which makes 352 
those mAbs potentially valuable reagents for analytical applications. The main metabolite, AZ-acid, was 353 
tightly recognized by three out of four mAbs coming from the immunizing hapten AZa6 (CR = 20–30%). This 354 
was also the case of AZ-enol, which was recognized even better than AZ-Z (CR = 25–85%). In fact, the IC50 355 
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values for these three compounds with mAbs AZa6#26, AZa6#210, and AZa6#31 were around 1 nM, a 356 
remarkable affinity for such small organic chemicals. The most notable antibody was mAb AZa6#210, which 357 
displayed the highest recognition for AZ-acid and AZ-enol, and almost the same affinity towards the two 358 
azoxystrobin estereoisomers (see Fig. 3 for a visual comparison with a more specific antibody). Accordingly, 359 
this mAb was the subject of further studies. 360 
3.3. Influence of buffer composition over the interaction of mAb AZa6#210 and azoxystrobin 361 
A multiparametric approach was carried out to evaluate the influence of pH and ionic strength over the 362 
antibody–analyte interaction. Three buffer systems, i.e. citrate (pKa2 = 4.8, pKa3 = 6.4), phosphate (pKa2 = 363 
7.2), and Tris (pKa = 8.1) were employed to adjust pH over a wide range of values, together with NaCl for 364 
ionic strength correction, as previously described (Suárez-Pantaleón et al., 2010). Also, several 365 
concentrations of Tween 20, a detergent usually employed in immunoassays to reduce unspecific 366 
interactions, were evaluated. A full factorial design, including 15 different buffers, was employed, fixing the 367 
center point conditions at 10 mM phosphate, 140 mM NaCl, pH 7.5, 0.025% (v/v) Tween 20. Parameters 368 
Amax and IC50 were taken as response values and fitted using the Minitab software as described. 369 
Little influence over the inhibition curve parameters were generally observed upon buffer composition 370 
(see the respective contour plots in Fig. S2). The Amax value remained stable at most of the pH, ionic 371 
strength, and Tween 20 evaluated conditions. Regarding the IC50, low pH and ionic strength values together 372 
with high Tween 20 concentrations seemed to be counterproductive. Tween 20 was well tolerated through 373 
a wide range of concentrations if conditions equivalent to those of PBS were maintained. For a better 374 
comprehension of the influence of pH and ionic strength, the degree of modification of both the Amax and 375 
IC50 was calculated taking as 100% those parameters obtained at the center point. When the contour plots 376 
of the percentage of variation of Amax and IC50 were overlaid (Fig. 4), a wide area of pH and ionic strength 377 
variations was clearly defined in which changes in those parameters remained tolerable; that is, between 378 
80 and 120%. A low dependence on the ionic strength conditions was revealed, whereas assay sensitivity 379 
slightly decreased at acidic pHs. Therefore, mAb AZa6#210 withstands modifications in the immunoreaction 380 
conditions, so it is a suitable candidate for the development of generic competitive immunoassays adapted 381 
to the analysis of azoxystrobin residues. If acidic samples were to be analyzed, assays could be run in 100 382 
mM phosphate, pH between 7.5 and 8.0, together with Tween 20 at a usual concentration (0.025%). 383 
  384 
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3.4. Analysis of mixtures of azoxystrobin stereoisomers 385 
As a proof-of-concept for the development of a generic rapid immunochemical assay, mixtures of 386 
azoxystrobin and AZ-Z in water were determined by cELISA using mAb AZa6#210 as bioreceptor. For 387 
comparison, the same samples were simultaneously determined using mAb AZo6#49, an antibody that 388 
displayed a CR value for AZ-Z of just 1%. Deionized water aliquots were spiked with the same total amount 389 
of fungicide (1000 ng mL−1) but at different proportions of the two isomers. When the sample just 390 
contained AZ-Z (Fig. 5, mixture A), only the mAb AZa6#210 was able to detect the analyte. Otherwise, in 391 
samples containing 100% azoxystrobin (E isomer) the same experimental concentration was obtained with 392 
both antibodies (Fig. 5, mixture G). Briefly, a clearly different output was obtained by both antibodies in 393 
mixtures containing less than 75% of AZ-E. This simple experiment clearly proved the feasibility of mAb 394 
AZa6#210 to determine samples containing both stereoisomers as a whole, which is a requirement in some 395 
international regulations.  396 
In summary, five relevant azoxystrobin transformation products were synthesized and characterized in 397 
detail by a number of different techniques, including MS, NMR, IR, HPLC-DAD, and TLC. With these 398 
degradates available, a collection of mAbs derived from haptens functionalized at selected sites was 399 
screened in order to find binders able to recognize the synthesized compounds. This approach allowed us 400 
to identify a mAb (AZa6#210) displaying high affinity values to azoxystrobin and to three important 401 
breakdown products; that is, AZ-Z, AZ-enol, and AZ-acid. The described antibody could be considered as a 402 
generic receptor and therefore suitable to be implemented in a number of different immunoanalytical 403 
platforms, such as ELISA, immunochromatographic strips, affinity columns, and biosensors, in order to 404 
analyze the total azoxystrobin content, including major metabolites and degradation products. 405 
 406 
  407 
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 493 
Figure legends 494 
 495 
Fig. 1. Synthesis scheme of azoxystrobin metabolites and degradation products 496 
 497 
Fig. 2. Mass spectra of azoxystrobin (a) and its transformation products, AZ-acid (b) and AZ-enol (c), 498 
showing the tentative fragmentation peak assignment. The mass spectra were measured in electron 499 
impact mode. A comparison of the high-mass regions of the mass spectra clearly shows the similar 500 
electron impact-induced fragmentation patterns showed by azoxystrobin and AZ-acid. 501 
 502 
Fig. 3. Inhibition curves for a generic mAb (AZa6#210) and for a more specific antibody (AZo6#49). The solid 503 
line with open symbols shows the azoxystrobin standard curve. Dashed lines are used for the curves of 504 
metabolites and degradation products: (▲) AZ-Z, (■) AZ-acid, (♦) AZ-enol, (▼) AZ-benzoic, and (●) AZ-505 
pyOH. 506 
 507 
Fig. 4. Overlaid contour plots of the Amax and IC50 variation (%) as a function of buffer pH and ionic strength 508 
(I). The white area sets the limits of acceptable pH and I conditions. 509 
 510 
Fig. 5. Analysis of mixtures of azoxystrobin and its (Z)-isomer using either the competitive assay with the 511 
generic (mAb AZa6#210, grey) or the specific (mAb AZo6#49, black) antibody. The sum of the 512 
concentrations of the two stereoisomers was kept constant to 1000 ng/mL. The percentage of 513 
azoxystrobin (E isomer) in each mixture was: A, 0%; B, 10%; C, 25%; D, 50%; E, 75%; F, 90%; G, 100%. 514 
 515 
 Table 1 
HPLC-DAD retention times (min) and TLC Rf  values 
of azoxystrobin transformation products 
 HPLC−DAD
a 
TLC
d 
Compound
 
MeOH–H2O
b
 MeCN–H2O
c 
CHCl3–MeOH
e 
AZ-benzoic (11) 12.5 9.2 0.10 
AZ-pyOH (8) 12.5 3.7 0.15 
AZ-acid (2) 17.5 9.2 0.21 
AZ-enol (3) 17.5 9.2 0.68 
AZ-Z (5) 18.6 11.4 0.75 
Azoxystrobin (1) 19.1 12.7 0.86 
a A Hitachi (Tokyo, Japan) L-2130 HPLC system, equipped with a Hitachi 
L-4500 diode array detector and a Merck KGaA (Darmstadt, Germany) 
LiChroCART RP-18 column (250 mm x 4 mm, 5 µm) was employed for 
chromatographic separations. 
b From 10% MeOH and 90% H2O, both containing 0.1% HCOOH, to 95% 
MeOH and 5% H2O in 20 min. Flow rate: 1 mL/min 
c From 40% MeCN and 60% H2O, both containing 0.1% HCOOH, to 75% 
MeCN and 25% H2O in 12 min, then from 75% MeCN and 25% H2O to 
100% MeCN and 0% H2O in 8 min. Flow rate: 1 mL/min 
d TLC was carried out on Pre-coated Merck Silica gel 60 F 254 TLC 
plates. The plates were visualized under UV light.  
e Mixture 98:2 (v/v). 
 
Table 1
 Table 2 
Recognition of azoxystrobin transformation products by the collection of mAbs (%)a 
 
 
 
 
  
mAb
 
AZ-Z AZ-acid AZ-enol AZ-benzoic AZ-pyOH 
AZa6#21 0.97 0.01 2.70 <0.01 <0.01 
AZa6#26 63.60 26.80 72.00 4.69 0.70 
AZa6#210 96.71 28.45 82.93 6.19 1.21 
AZa6#31 45.03 20.43 27.65 0.37 0.11 
      AZb6#22 4.39 6.36 0.92 0.01 <0.01 
AZb6#24 3.82 5.61 0.79 0.01 <0.01 
AZb6#38 0.99 0.03 1.94 <0.01 0.03 
AZb6#43 3.97 0.69 3.05 <0.01 <0.01 
      AZc6#22 1.22 0.01 0.19 <0.01 0.01 
AZc6#25 15.17 0.02 0.07 <0.01 <0.01 
AZc6#26 38.23 0.06 8.89 <0.01 <0.02 
AZc6#27 3.30 0.03 3.58 <0.01 <0.01 
      AZo6#41 1.02 0.03 1.61 0.01 <0.01 
AZo6#43 1.03 0.02 2.08 0.01 <0.01 
AZo6#45 2.95 0.06 73.03 <0.01 <0.01 
AZo6#49 1.01 0.02 1.69 <0.01 <0.01 
a Values correspond to cross-reactivities referred to the IC50 (nM) of azoxystrobin, which is considered 100%. Assays were carried out in the 
homologous indirect cELISA format, using for every combination of mAb and conjugate those concentrations resulting in the lowest IC50 value for 
azoxystrobin with an Amax higher than 1.0. 
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